Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Topics:
Thoracic Malignancies
•
Medical Oncology
Would you consider switching capmatinib to tepotinib or vice versa due to grade 3 hepatotoxicity in a patient with metastatic NSCLC with MET Exon 14 skipping mutation?
Related Questions
In patients with driver mutation positive NSCLC who have progressed on targeted therapy and are planned for chemotherapy as the next line of treatment, for which driver alterations do you add in IO and which do you omit IO?
Would you offer any additional adjuvant therapy after platinum based chemotherapy for patients with resected PD-L1 positive Stage II-III lung adenocarcinoma with EGFR exon 20 insertions?
How do the results of TROPION-Lung01 Phase III trial change your practice in the management of locally advanced or metastatic NSCLC?
What second line therapy do you use for metastatic thymoma that recurs following CAP?
What would be your approach in a patient who presented with a solitary brain metastasis that resolved after chemo without local therapy?
What initial therapy do you offer elderly patients with metastatic NSCLC with MET amplification and PD-L1 >50%?
What is your approach to isolated thoracic recurrence of NSCLC in an otherwise asymptomatic patient with prior chemoradiation and immunotherapy?
How are you approaching patients who receive neoadjuvant chemo immunotherapy for resectable NSCLC who after completion of neoadjuvant treatment are no longer surgical candidates due to factors such as toxicity, decline in PS, or patient preference?
Is dyspnea without radiation pneumonitis a side effect of lung radiation?
Which regimen do you recommend for chemoradiation for a patient with locally advanced, inoperable thymic tumor in the setting of CKD Stage III?